Payment overview · 2025
General Payments
$672.02
30 reported records · 13 companies
Healthcare provider profile · identity verified
Jason Mark Nesmith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CAIRO, GA · NPI 1881858686
Verified facts
What the public records show
CMS Open Payments records show Jason Mark Nesmith, M.D. received $672.02 in general payments during 2025 across 30 reported records.
Exact Sciences Corporation accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $150.80 | 22.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.60 | 15.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.90 | 11.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.30 | 9.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.78 | 8.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.99 | 7.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.36 | 6.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.46 | 4.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $23.24 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.83 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.50 | 3.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.84 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.42 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.02 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $119.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.60 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.90 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.30 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.78 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.50 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 298 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
298 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 974 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 776 | 154 |
| Losartan Potassium | Losartan Potassium | 600 | 143 |
| Furosemide | Furosemide | 568 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 518 | 94 |
| Omeprazole | Omeprazole | 515 | 120 |
| Gabapentin | Gabapentin | 457 | 106 |
| Famotidine | Famotidine | 404 | 81 |
| Metformin Hcl | Metformin Hcl | 391 | 100 |
| Carvedilol | Carvedilol | 350 | 62 |
| Lisinopril | Lisinopril | 329 | 86 |
| Eliquis | Apixaban | 298 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 293 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 63 |
| Simvastatin | Simvastatin | 288 | 78 |
| Citalopram Hbr | Citalopram Hydrobromide | 275 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 61 |
| Potassium Chloride | Potassium Chloride | 246 | 47 |
| Allopurinol | Allopurinol | 239 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 57 |
| Trazodone Hcl | Trazodone Hcl | 224 | 38 |
| Tramadol Hcl | Tramadol Hcl | 202 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 59 |
| Meloxicam | Meloxicam | 176 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 171 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 42 |
| Glipizide | Glipizide | 150 | 39 |
| Nifedipine Er | Nifedipine | 149 | 28 |
| Montelukast Sodium | Montelukast Sodium | 148 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 41 |
| Mounjaro | Tirzepatide | 134 | 21 |
| Farxiga | Dapagliflozin Propanediol | 133 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 26 |
| Pregabalin | Pregabalin | 129 | 21 |
| Methylprednisolone | Methylprednisolone | 128 | 105 |
| Donepezil Hcl | Donepezil Hcl | 125 | 16 |
| Sertraline Hcl | Sertraline Hcl | 118 | 25 |
| Risperidone | Risperidone | 112 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 21 |
| Ozempic | Semaglutide | 106 | 21 |
| Glimepiride | Glimepiride | 103 | 24 |
| Atenolol | Atenolol | 98 | 25 |
| Alendronate Sodium | Alendronate Sodium | 96 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 17 |
| Bumetanide | Bumetanide | 95 | 23 |
| Finasteride | Finasteride | 92 | 16 |
| Alprazolam | Alprazolam | 91 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 22 |
| Azithromycin | Azithromycin | 83 | 70 |
| Buspirone Hcl | Buspirone Hcl | 83 | 12 |
| Jardiance | Empagliflozin | 83 | 18 |
| Mirtazapine | Mirtazapine | 82 | 12 |
| Linzess | Linaclotide | 80 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 11 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Memantine Hcl | Memantine Hcl | 72 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 70 | suppressed |
| Sucralfate | Sucralfate | 68 | 13 |
| Chlorthalidone | Chlorthalidone | 66 | 15 |
| Colchicine | Colchicine | 64 | 15 |
| Levetiracetam | Levetiracetam | 64 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 19 |
| Entresto | Sacubitril/Valsartan | 60 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Fluconazole | Fluconazole | 56 | 33 |
| Valacyclovir | Valacyclovir Hcl | 54 | 12 |
| Celecoxib | Celecoxib | 52 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 16 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Amoxicillin | Amoxicillin | 49 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 42 |
| Meclizine Hcl | Meclizine Hcl | 46 | 17 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 41 | 39 |
| Baclofen | Baclofen | 40 | 13 |
| Lorazepam | Lorazepam | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 18 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Nystatin | Nystatin | 36 | 20 |
| Promethazine Hcl | Promethazine Hcl | 36 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 13 |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | 18 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 17 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Estradiol | Estradiol | 22 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 22 | 21 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $672.02 · 30 records | Exact Sciences Corporation | AIRSUPRA, Andembry, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, INSPIRE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error